Drug Profile
LG 631
Alternative Names: LG631; LG631-CD34; Stem cell therapy - Case Western Reserve University/Opus BioLatest Information Update: 13 Apr 2016
Price :
$50
*
At a glance
- Originator Case Western Reserve University
- Developer Case Western Reserve University; Opus Bio
- Class Chemoprotectants; Gene therapies; Haematopoietic stem cells therapies; Stem cell therapies
- Mechanism of Action Cell replacements; Gene transference; MGMT protein replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Suspended Chemotherapy-induced damage
Most Recent Events
- 27 Jul 2015 Phase-I clinical trials in Chemotherapy induced damage in USA (Parenteral)
- 14 Aug 2014 Lentigen Corporation starts operating as Opus Bio and gains certain rights to use lentiviral technology
- 14 Aug 2014 Miltenyi Biotec acquires the cell and gene therapy assets of Lentigen Corporation, and forms Lentigen Technology